Table 1.
Summary of BET inhibitor clinical trials (open Dec. 2017).
| Compound | Company | Indications | Phases | Completion Date | NCT Number |
|---|---|---|---|---|---|
| FT-1101 | Forma Therapeutics, Inc. (Watertown, MA, USA) | Acute Myeloid Leukemia/Acute Myelogenous Leukemia/Myelodysplastic Syndrome | Phase 1 | August 2018 | NCT02543879 |
| RO6870810 * | Hoffmann-La Roche (Basel, Switzerland) | Multiple Myeloma | Phase 1 | 15 January 2020 | NCT03068351 |
| CPI-0610 | Constellation Pharmaceuticals (Cambridge, MA, USA) | Lymphoma | Phase 1 | July 2018 | NCT01949883 |
| Multiple Myeloma | Phase 1 | March 2019 | NCT02157636 | ||
| Acute Myeloid Leukemia/Myelodysplastic Syndrome (MDS)/ Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable/Myelofibrosis | Phase 1 | January 2019 | NCT02158858 | ||
| Peripheral Nerve Tumors | Phase 2 | March 2020 | NCT02986919 | ||
| GSK525762 | GSK (Brentford, UK) | Cancer | Phase 1 | 24 February 2020 | NCT01943851 |
| Carcinoma, Midline | Phase 1 | 9 September 2019 | NCT01587703 | ||
| ZEN003694 ** | Zenith Epigenetics (San Francisco, CA, USA) | Metastatic Castration-Resistant Prostate Cancer | Phase 1 | April 2018 | NCT02711956 |
| BMS-986158 | Bristol-Myers Squibb (New York, NY, USA) | Multiple Indications Cancer | Phase 1/Phase 2 | 17 December 2018 | NCT02419417 |
* Alone or in combination with Daratumumab; ** in combination with Enzalutamide.